21 CFR 314, Subpart D - FDA Action on Applications and Abbreviated Applications
- § 314.100 — Timeframes for reviewing applications and abbreviated applications.
- § 314.101 — Filing an application and receiving an abbreviated new drug application.
- § 314.102 — Communications between FDA and applicants.
- § 314.103 — Dispute resolution.
- § 314.104 — Drugs with potential for abuse.
- § 314.105 — Approval of an application and an abbreviated application.
- § 314.106 — Foreign data.
- § 314.107 — Effective date of approval of a 505(b)(2) application or abbreviated new drug application under section 505(j) of the act.
- § 314.108 — New drug product exclusivity.
- § 314.110 — Complete response letter to the applicant.
- § 314.120 — [Reserved]
- § 314.122 — Submitting an abbreviated application for, or a 505(j)(2)(C) petition that relies on, a listed drug that is no longer marketed.
- § 314.125 — Refusal to approve an application.
- § 314.126 — Adequate and well-controlled studies.
- § 314.127 — Refusal to approve an abbreviated new drug application.
- § 314.150 — Withdrawal of approval of an application or abbreviated application.
- § 314.151 — Withdrawal of approval of an abbreviated new drug application under section 505(j)(5) of the act.
- § 314.152 — Notice of withdrawal of approval of an application or abbreviated application for a new drug.
- § 314.153 — Suspension of approval of an abbreviated new drug application.
- § 314.160 — Approval of an application or abbreviated application for which approval was previously refused, suspended, or withdrawn.
- § 314.161 — Determination of reasons for voluntary withdrawal of a listed drug.
- § 314.162 — Removal of a drug product from the list.
- § 314.170 — Adulteration and misbranding of an approved drug.
Title 21 published on 2012-04-01
no entries appear in the Federal Register after this date.
This is a list of United States Code sections, Statutes at Large, Public Laws, and Presidential Documents, which provide rulemaking authority for this CFR Part.
This list is taken from the Parallel Table of Authorities and Rules provided by GPO [Government Printing Office].
It is not guaranteed to be accurate or up-to-date, though we do refresh the database weekly. More limitations on accuracy are described at the GPO site.
Title 21 published on 2012-04-01
The following are ALL rules, proposed rules, and notices (chronologically) published in the Federal Register relating to 21 CFR 314 after this date.
GPO FDSys XML | Text type regulations.gov FR Doc. 2013-02528 RIN Docket No. FDA-2013-N-0059 DEPARTMENT OF HEALTH AND HUMAN SERVICES, Food and Drug Administration Notification of an initiative; request for comments and information. Submit either electronic or written comments by March 8, 2013. 21 CFR Parts 201, 314, and 601 The Food and Drug Administration (FDA) is announcing the establishment of a docket to receive comments on the proposed implementation of FDA's Prescription Drug Labeling Improvement and Enhancement Initiative and on a proposed pilot project relating to the voluntary conversion of labeling to the “Physician Labeling Rule (PLR)” format described in the 2006 FDA final rule, “Requirements on Content and Format of Labeling for Human Prescription Drug and Biological Products.” The purpose of the initiative and the pilot project is to enhance the safe and effective use of prescription drugs by facilitating optimal communication through labeling. FDA is seeking public comment on this initiative, and the pilot project, particularly from stakeholders who develop and use prescription drug labeling. Comments received from stakeholders will assist the Agency in identifying and addressing feasibility and implementation issues associated with this initiative.